This suggests that the dopamine receptor signaling pathway has potential to serve as a therapeutic target and that targeting the DRD2/β-catenin/ZEB1 signaling axis could potentially be a promising therapeutic strategy in clinical management of patients with CRC [77]. This evidence concerns the gene DRD2 and colorectal carcinoma.